rss
Gut 53:641-648 doi:10.1136/gut.2003.024836
  • Small intestine

In vivo targeting of intestinal and extraintestinal transglutaminase 2 by coeliac autoantibodies

  1. I R Korponay-Szabó1,
  2. T Halttunen2,
  3. Z Szalai3,
  4. K Laurila2,
  5. R Király4,
  6. J B Kovács5,
  7. L Fésüs4,
  8. M Mäki2
  1. 1Paediatric Research Centre, Tampere University Hospital, Tampere, Finland, and Department of Gastroenterology-Nephrology, Heim Pál Children’s Hospital, Budapest, Hungary
  2. 2Paediatric Research Centre, Tampere University Hospital, Tampere, Finland
  3. 3Department of Dermatology, Heim Pál Children’s Hospital, Budapest, Hungary
  4. 4Department of Biochemistry and Molecular Biology, Medical and Health Science Centre, University of Debrecen, Debrecen, Hungary
  5. 5Department of Gastroenterology-Nephrology, Heim Pál Children’s Hospital, Budapest, Hungary
  1. Correspondence to:
    Dr M Mäki
    Coeliac Disease Study Group, Paediatric Research Centre, Building FM3, University of Tampere, FIN-33014, Finland; markku.makiuta.fi
  • Accepted 26 November 2003

Abstract

Background: IgA class serum autoantibodies against type 2 (tissue) transglutaminase (TG2) bind to both intestinal and extraintestinal normal tissue sections in vitro, eliciting endomysial, reticulin, and jejunal antibody reactions. It is not known whether similar binding also occurs in coeliac patients in vivo, and may thereby contribute to disease manifestations.

Aims: To investigate intestinal and extraintestinal coeliac tissues for the presence of in vivo bound TG2 specific IgA and its relation to small intestinal mucosal atrophy.

Patients: We investigated jejunal samples with normal villous morphology from 10 patients with developing coeliac disease who subsequently progressed to a flat lesion, from 11 patients with dermatitis herpetiformis, and from 12 non-coeliac controls. Six extrajejunal biopsy samples (liver, lymph node, muscle, appendix), obtained based on independent clinical indications from patients with active coeliac disease, were also studied.

Methods: Double colour immunofluorescent studies for in situ IgA, TG2, and laminin were performed. IgA was eluted from tissue sections and tested for TG2 specificity by enzyme linked immunosorbent assay and indirect immunofluorescence.

Results: IgA (in one IgA deficient case IgG) deposition on extracellularly located TG2 was detected in jejunal and extrajejunal specimens of all coeliac patients, and also in seven of 11 dermatitis herpetiformis patients, of whom two had no circulating endomysial antibodies. IgA eluted from extraintestinal coeliac tissues was targeted against TG2.

Conclusions: Coeliac IgA targets jejunal TG2 early in disease development even when endomysial antibodies are not present in the circulation. Extraintestinal target sites of coeliac IgA further indicate that humoral immunity may have a pathogenetic role.

Footnotes